MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


RNS News Service

I confirm that I am accessing this story in my capacity as a private investor and NOT for professional purposes.

Requisition notice and Progress of CEO appointment

RNS

RNS Number : 0918D
InnovaDerma PLC
23 October 2020
 

  InnovaDerma PLC 

("InnovaDerma" or the "Company")

Requisition notice, adjournment of the AGM and progress of CEO appointment

InnovaDerma (LSE: IDP), a UK developer of beauty, personal care and life science products, announces that it has received a requisition notice (the "Requisition Notice") from Edale Capital LLP ("Edale"), a shareholder holding in excess of 5% of the Company's voting capital.  The Requisition Notice proposed resolutions to be held at the upcoming AGM for the re-election of Joseph Bayer and Rodney Turner in line with good corporate governance. The Requisition Notice also proposed the appointment of a new director.

Having consulted with its advisors, the Board believes that the best way to comply with the intention of the Requisition Notice is to call a new General Meeting to consider these resolutions. So that shareholders can consider these resolutions at the same time as the AGM resolutions, the Board intends to adjourn the upcoming AGM scheduled for 11 November to the same date and time as the new General Meeting.

It is expected that the adjourned AGM and the new General Meeting will be held in the second half of November. The Company is working with its advisors to put in place the procedures to allow this to happen as smoothly as possible. A formal notice of General Meeting will be produced and issued as soon as possible.

The Board continues to believe that good corporate governance is important to the operation of the Company and supports the proposal to have all directors stand for re-election. The Board is also in the process of interviewing the new director and carrying out normal due diligence on the individual. Following this process, the Board hopes to be able to make a recommendation to shareholders in favour of the appointment of this director.

As announced on 5 August, the Company commenced a formal process for the identification and appointment of a new CEO who will be based in the UK and will be appointed to the Board.  The Company is pleased to report the search is progressing very well.

Further announcements will be made in due course.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Further enquiries

 

InnovaDerma

Joe Bayer

 

 

+61 417 870 743

 

finnCap Ltd

Geoff Nash/Kate Bannatyne

Alice Lane/Manasa Patil - Corporate Broking

 

+44 (0)207 220 0500

www.finncap.com

TB Cardew

Shan Shan Willenbrock/Tom Allison

Olivia Rosser

 

+ 44 (0)20 7930 0777

innovaDerma@tbcardew.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCXXLFLBBLBFBB